glial-cell-mechanisms

Migration, Crosslink

📖

glial-cell-mechanisms

active

wiki page Created: 2026-04-02T07:20:14 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-aaic-2026-glial-cell-mechani

📖 Wiki Page

general1065 wordssynced 2026-04-02

AAIC 2026: Glial Cell Mechanisms

Conference: [AAIC 2026](/events/aaic-2026) | Dates: July 12-15, 2026 | Location: Excel London, UK

Overview

Glial cells—microglia and astrocytes—have emerged as central players in Alzheimer's disease pathogenesis and represent promising therapeutic targets. AAIC 2026 features extensive research on glial biology, reflecting the field's recognition that neurodegenerative processes involve complex non-neuronal interactions[@aao2026].

Microglia in Alzheimer's Disease

Disease-Associated Microglia (DAM)

Disease-associated microglia represent a distinct microglial activation state observed in Alzheimer's disease and other neurodegenerative conditions[@deczkowska2023]:

flowchart TD A["Homeostatic Microglia"] --> B["Stage 1 DAM: TREM2-independent"] B --> C["Stage 2 DAM: TREM2-dependent"] C --> D["Neurodegeneration Associated"] A -->|"Aging, Abeta"| B B -->|"TREM2 activation"| C C -->|"Chronic inflammation"| D style A fill:#0a1929,stroke:#01579b,color:#e0e0e0 style B fill:#3e2200,stroke:#e65100,color:#e0e0e0 style C fill:#2d0f0f,stroke:#c62828,color:#e0e0e0 style D fill:#2d0f0f,stroke:#ad1457,color:#e0e0e0

Key DAM Characteristics:

Stage 1 DAM: Initial response to amyloid pathology; TREM2-independent
Stage 2 DAM: Requires TREM2 signaling; enhanced phagocytic capacity
Stage 3 DAM: Associated with neurodegeneration; may become maladaptive

...

AAIC 2026: Glial Cell Mechanisms

Conference: [AAIC 2026](/events/aaic-2026) | Dates: July 12-15, 2026 | Location: Excel London, UK

Overview

Glial cells—microglia and astrocytes—have emerged as central players in Alzheimer's disease pathogenesis and represent promising therapeutic targets. AAIC 2026 features extensive research on glial biology, reflecting the field's recognition that neurodegenerative processes involve complex non-neuronal interactions[@aao2026].

Microglia in Alzheimer's Disease

Disease-Associated Microglia (DAM)

Disease-associated microglia represent a distinct microglial activation state observed in Alzheimer's disease and other neurodegenerative conditions[@deczkowska2023]:

Mermaid diagram (expand to render)

Key DAM Characteristics:

Stage 1 DAM: Initial response to amyloid pathology; TREM2-independent
Stage 2 DAM: Requires TREM2 signaling; enhanced phagocytic capacity
Stage 3 DAM: Associated with neurodegeneration; may become maladaptive

DAM Markers:

Upregulated: [TYROBP](/genes/tyrobp), [CSF1](/genes/csf1), [APOE](/genes/apoe), [AXL](/genes/axl)
Downregulated: [CX3CR1](/genes/cx3cr1), [P2RY12](/genes/p2ry12)

TREM2 Signaling Pathway

[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) is a critical regulator of microglial function:

Mermaid diagram (expand to render)

TREM2 Variants and AD Risk:

| Variant | Risk Effect | Functional Impact |
|---------|-------------|-------------------|
| R47H | 3-4x increased | Impaired lipid sensing |
| R62H | 2-3x increased | Reduced ligand binding |
| T96I | 1.5-2x increased | Altered signaling |

TREM2-Targeting Therapies at AAIC 2026:

| Program | Company | Mechanism | Stage |
|---------|---------|-----------|-------|
| AL002 | Alector/GSK | TREM2 agonist | Phase II |
| PY314 | Pyroneer | TREM2 agonist | Phase I |
| SAR-443122 | Sanofi | TREM2 inverse agonist | Phase I |

See [TREM2 Microglia Pathway](/mechanisms/trem2-microglia-pathway) for detailed mechanism.

Microglial Priming

Microglial priming describes the sensitization of microglia to produce exaggerated inflammatory responses:

Priming Factors:

Aging
[APOE4](/genes/apoe4) allele carriage
Previous neuroinflammatory events
Systemic infection

Primed Microglia Characteristics:

Enhanced baseline cytokine production
Exaggerated response to secondary challenges
Impaired surveillance function

CSF1R Targeting

[CSF1R](/proteins/csf1r) (Colony Stimulating Factor 1 Receptor) regulates microglial survival and proliferation:

Mermaid diagram (expand to render)

Clinical Considerations:

CSF1R blockade reduces microglial numbers
Risk of impairing beneficial surveillance functions
May need cell-type specific targeting

Complement System in Neurodegeneration

The complement system mediates synaptic elimination by microglia:

Mermaid diagram (expand to render)

Complement Therapeutics

| Target | Drug | Company | Status |
|--------|------|---------|--------|
| C1q | ANX007 | Annexon | Phase II |
| C3 | Pegcetacoplan | Apellis | Phase II |
| C5 | Eculizumab | Alexion | Pilot |

See [Complement-Mediated Synapse Loss](/mechanisms/complement-mediated-synapse-loss).

Astrocyte Reactivity

[Reactive astrocytes](/cell-types/reactive-astrocytes-overview) adopt distinct phenotypes in neurodegeneration[@liddelow2017]:

A1 vs A2 Classification

Mermaid diagram (expand to render)

A1 Astrocyte Markers:

[GFAP](/proteins/gfap) (general marker)
[S100A10](/proteins/s100a10)
[Serpina3n](/genes/serpina3n)

A2 Astrocyte Markers:

[S100A4](/proteins/s100a4)
[CD44](/genes/cd44)
[Vim](/genes/vim)

Astrocyte-Neuron Interactions

Neurotoxic Effects:

Impaired [glutamate](/mechanisms/glutamate-excitotoxicity) homeostasis (reduced EAAT1/2)
Release of pro-inflammatory cytokines
Complement component production

Therapeutic Implications:

Block A1-inducing factors (IL-1α, TNF, C1q)
Promote A2 phenotype conversion
Enhance astrocyte support functions

Glial Crosstalk

Microglia-Astrocyte Communication

Mermaid diagram (expand to render)

Neuroimmune Cross-Talk

Gut-Brain Axis:

[Microbiome](/mechanisms/microbiome-gut-brain-axis)-derived SCFAs modulate glial function
Leaky gut increases systemic LPS triggering CNS inflammation
Microbiome signatures differ in AD vs. controls

Peripheral Immune System:

[Monocyte](/cell-types/monocytes) infiltration (CCR2+)
[NK cell](/cell-types/natural-killer-cells) dysfunction
[T cell](/cell-types/t-cells) infiltration (CD8+, CD4+)

Therapeutic Targeting of Glial Cells

Current Approaches

| Strategy | Target | Approach | Stage |
|----------|--------|----------|-------|
| TREM2 agonism | TREM2 | Enhance phagocytosis | Phase II |
| CSF1R inhibition | CSF1R | Reduce DAM | Preclinical |
| Complement inhibition | C1q, C3 | Prevent synapse loss | Phase II |
| Astrocyte modulation | A1→A2 shift | Reprogram phenotype | Preclinical |

Emerging Strategies

Microglial replacement: Bone marrow transplant approaches
Glial progenitor targeting: Induced pluripotent stem cell-derived glia
Gene therapy: Modulate glial gene expression in vivo

Glial Biomarkers

Microglial Biomarkers

| Biomarker | Source | Significance |
|-----------|--------|--------------|
| [sTREM2](/proteins/trem2) | CSF/Plasma | TREM2 shedding, disease progression |
| [YKL-40](/proteins/ykl40) | CSF/Plasma | Astrocyte activation |
| [IBA1](/proteins/iba1) | Tissue | Microglial activation marker |

Astrocyte Biomarkers

| Biomarker | Source | Significance |
|-----------|--------|--------------|
| [GFAP](/proteins/gfap) | Plasma | Reactive astrogliosis |
| S100B | CSF/Plasma | Astrocyte damage |

Notable Sessions at AAIC 2026

Symposia

"Microglia in Alzheimer's Disease: From Biology to Therapeutics"
"Astrocyte Reactivity: Good, Bad, or Both?"
"Complement-Mediated Synaptic Loss: New Therapeutic Targets"

Workshops

"Glial Cell Models for Drug Discovery"
"In Vivo Imaging of Glial Activation"

[Neuroinflammation in AD](/mechanisms/neuroinflammation-ad-pd-als)
[TREM2 Signaling Pathway](/mechanisms/trem2-signaling)
[Disease-Associated Microglia](/cell-types/disease-associated-microglia)
[Reactive Astrocytes Overview](/cell-types/reactive-astrocytes-overview)
[Complement System Pathway](/mechanisms/complement-system-pathway)
[AAIC 2026: Neuroinflammation](/events/aaic-2026/neuroinflammation)

References

[Wang S, et al., Microglia in Alzheimer's disease: from pathogenesis to therapeutic targeting. Signal Transduct Target Ther. 2023 (2023)](https://doi.org/10.1038/s41392-023-01428-9)

[Deczkowska A, et al., Disease-associated microglia: A universal target for neurodegeneration. Cell. 2023 (2023)](https://doi.org/10.1016/j.cell.2023.09.012)

[Liddelow SA, et al., Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017 (2017)](https://doi.org/10.1038/nature21359)

📖 View canonical wiki page →

Related Entities

events-aaic-2026-glial-cell-mechanisms

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-aaic-2026-glial-cell-mechanisms
kg_node_id	None
entity_type	general
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4050c3d71718
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-aaic-2026-glial-cell-mechanisms'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

37

Outgoing

60

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

glial-cell-mechanisms

AAIC 2026: Glial Cell Mechanisms

Overview

Microglia in Alzheimer's Disease

Disease-Associated Microglia (DAM)

AAIC 2026: Glial Cell Mechanisms

Overview

Microglia in Alzheimer's Disease

Disease-Associated Microglia (DAM)

TREM2 Signaling Pathway

Microglial Priming

CSF1R Targeting

Complement System in Neurodegeneration

Complement Therapeutics

Astrocyte Reactivity

A1 vs A2 Classification

Astrocyte-Neuron Interactions

Glial Crosstalk

Microglia-Astrocyte Communication

Neuroimmune Cross-Talk

Therapeutic Targeting of Glial Cells

Current Approaches

Emerging Strategies

Glial Biomarkers

Microglial Biomarkers

Astrocyte Biomarkers

Notable Sessions at AAIC 2026

Symposia

Workshops

See Also

References

💬 Discussion

📗 Cite This Artifact

glial-cell-mechanisms

AAIC 2026: Glial Cell Mechanisms

Overview

Microglia in Alzheimer's Disease

Disease-Associated Microglia (DAM)

AAIC 2026: Glial Cell Mechanisms

Overview

Microglia in Alzheimer's Disease

Disease-Associated Microglia (DAM)

TREM2 Signaling Pathway

Microglial Priming

CSF1R Targeting

Complement System in Neurodegeneration

Complement Therapeutics

Astrocyte Reactivity

A1 vs A2 Classification

Astrocyte-Neuron Interactions

Glial Crosstalk

Microglia-Astrocyte Communication

Neuroimmune Cross-Talk

Therapeutic Targeting of Glial Cells

Current Approaches

Emerging Strategies

Glial Biomarkers

Microglial Biomarkers

Astrocyte Biomarkers

Notable Sessions at AAIC 2026

Symposia

Workshops

Related NeuroWiki Content

See Also

References

💬 Discussion